About this Research Topic
Breast cancer remains the most common cancer in women worldwide and is found to be highly heterogeneous. Depending on the expression of the estrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2 (HER2), breast cancer can be classified as luminal, HER2-enriched and triple-negative. Except for surgery, each sub-type possesses different treatment strategies, such as endocrine therapy for luminal breast cancer and anti-HER2-based targeted therapy for HER2-enriched breast cancer. Hence, more precise clustering systems are being developed by researchers to illustrate the comprehensive profiling of breast cancer, resorting to both intrinsic signals and extrinsic microenvironment. It is urgent that researchers generate more convincing biomarkers to better predict prognosis, together with novel therapeutic targets for treating different clusters of breast cancer patients.
This Research Topic highlights the need to find more meaningful breast cancer biomarkers and druggable targets based on originality, importance and timeliness. Although the 5-year overall survival rate of early breast cancer is over 90%, many patients still undergo recurrence, metastasis and drug resistance even after standard treatment in clinical practice. Besides, drawing from the great success that we have achieved by treating breast cancer based on molecular subtypes (luminal, HER2-enriched and triple-negative), increasingly accurate subtyping methods are still underway, such as classical VICC and FUSCCTNBC classification system of triple-negative BC.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
• Identification and validation of clinically significant novel biomarkers to predict therapy response and prognosis of breast cancer;
• Data analysis and validation identifying novel features of breast cancer to better guide future treatment;
• Underlying mechanisms of recurrence or metastasis of breast cancer;
• Identification of druggable targets in breast cancerand classified subgroups;
• Preclinical research translating molecular targets into clinical practice;
• Clinical trials illustrating response to therapy in breast cancer;
• Population-based studies of clinical features of breast cancer.
To be considered for publication, studies must demonstrate the applicability of anticancer modalities on a minimum of two well-authenticated cancer cell lines. Studies consisting solely of in silico investigation without experimental or in situ validation to support conclusions are not in scope of this Research Topic.
This Research Topic highlights the need to find more meaningful breast cancer biomarkers and druggable targets based on originality, importance and timeliness. Although the 5-year overall survival rate of early breast cancer is over 90%, many patients still undergo recurrence, metastasis and drug resistance even after standard treatment in clinical practice. Besides, drawing from the great success that we have achieved by treating breast cancer based on molecular subtypes (luminal, HER2-enriched and triple-negative), increasingly accurate subtyping methods are still underway, such as classical VICC and FUSCCTNBC classification system of triple-negative BC.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
• Identification and validation of clinically significant novel biomarkers to predict therapy response and prognosis of breast cancer;
• Data analysis and validation identifying novel features of breast cancer to better guide future treatment;
• Underlying mechanisms of recurrence or metastasis of breast cancer;
• Identification of druggable targets in breast cancerand classified subgroups;
• Preclinical research translating molecular targets into clinical practice;
• Clinical trials illustrating response to therapy in breast cancer;
• Population-based studies of clinical features of breast cancer.
To be considered for publication, studies must demonstrate the applicability of anticancer modalities on a minimum of two well-authenticated cancer cell lines. Studies consisting solely of in silico investigation without experimental or in situ validation to support conclusions are not in scope of this Research Topic.
Keywords: Breast Cancer, Biomarker, Therapeutic Target, Predictive, Prognosis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
